DexCom (DXCM) vs Medline (MDLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medline is the larger company by market cap ($48.22 billion vs $31.65 billion), about 1.5 times the size. On valuation, Medline trades at a lower forward P/E (22.7x vs 26.8x for DexCom). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | MDLN |
|---|---|---|
| Share price | $83.86 | $35.84 |
| Market cap | $31.65B | $48.22B |
| 1-day change | -0.65% | +0.28% |
| YTD return | +27.18% | -14.90% |
| 1-year return | +24.54% | — |
| 5-year return | -37.99% | — |
| P/E ratio (TTM) | 33.28 | 89.60 |
| Forward P/E | 26.82 | 22.73 |
| EPS (TTM) | $2.52 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $28.43B |
| Revenue growth (YoY) | +15.60% | — |
| Net income (latest FY) | $836.30M | $1.16B |
| Gross margin | 60.10% | 26.44% |
| Operating margin | 19.56% | 7.78% |
| Net margin | 17.94% | 4.08% |
| 52-week high | $92.59 | $50.88 |
| 52-week low | $54.11 | $31.49 |
| Distance from 52-week high | -9.43% | -29.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.75% | +24.16% |
| Average volume | 4.43M | 7.66M |
| Shares outstanding | 377.36M | 877.35M |
| Employees | 11,000 | 45,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline trades at a higher earnings multiple (89.6x vs 33.3x trailing P/E).
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 4.1 cents for Medline.
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
DXCM vs MDLN FAQ
Which is bigger, DexCom or Medline?
Medline (MDLN) is larger, with a market capitalization of $48.22B compared with $31.65B for DexCom (DXCM).
Which has the lower P/E ratio, DXCM or MDLN?
DXCM has the lower trailing P/E at 33.3, versus 89.6 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DexCom and Medline in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.